Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 2, 2021

Primary Completion Date

April 30, 2025

Study Completion Date

October 31, 2025

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

Azacitidine

Given IV or SC

DRUG

Uproleselan

Given IV

DRUG

Venetoclax

Given PO

Trial Locations (1)

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors

collaborator

GlycoMimetics Incorporated

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Brian Jonas

OTHER

NCT04964505 - Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter